Cognitive Research Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: St Petersburg FL United States (2006)

Organization Overview

First Clinical Trial
2007
NCT00531947
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cognitive Research Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Ataxia (Phase 3)

Bipolar Disorder (Phase 3)

Cerebellar Ataxia (Phase 3)

Dementia (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Disease (Phase 3)

Mood Disorders (Phase 3)

Motor Neuron Disease (Phase 1)

Nocturia (Phase 4)

Psychomotor Agitation (Phase 3)

Psychotic Disorders (Phase 3)

Renal Insufficiency (Phase 1)

Schizophrenia (Phase 3)

Sclerosis (Phase 1)

Spinocerebellar Ataxias (Phase 3)

Spinocerebellar Degenerations (Phase 3)

Substance Withdrawal Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 14